SBC Medical Group (NASDAQ:SBC) Posts Quarterly Earnings Results

Key Points

• SBC Medical Group reported mixed quarterly results: earnings per share came in at $0.10, below the $0.12 analyst consensus, while revenue reached $49.19 million, exceeding estimates of $45.37 million.
• Operational performance strengthened: revenue rose 13% to approximately $49 million, adjusted EBITDA increased 32% to $20 million, and clinic visits and average spending per visit both grew. Management said domestic aesthetic medicine is recovering following marketing, pricing and treatment reforms.
• Growth plans remain broad but challenges persist: SBC is deploying AI, expanding into non-aesthetic healthcare and international markets, and targeting 1,000 clinics by 2035. A weaker yen, intense Japanese competition and higher SG&A remain headwinds, while analysts maintain a consensus “Hold” rating.

SBC Medical Group (NASDAQ:SBC - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.10 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.02), FiscalAI reports. The company had revenue of $49.19 million for the quarter, compared to analyst estimates of $45.37 million. SBC Medical Group had a return on equity of 15.90% and a net margin of 24.09%.

Here are the key takeaways from SBC Medical Group's conference call:

• Positive Sentiment: SBC reported strong second-quarter results, with revenue up 13% to $49 million, adjusted EBITDA up 32% to $20 million, and a 41% margin. Clinic locations increased to 287, visits rose 10%, and average spend per visit increased 9%.
• Positive Sentiment: Management said domestic aesthetic medicine has re-accelerated after marketing, pricing, and treatment reforms, with same-clinic revenue up 6% and first-half transaction value up 19%. It expects a more favorable competitive environment as the pace of new clinic openings slows.
• Positive Sentiment: AI is being deployed across customer service, marketing, call-center operations, site selection, and employee training, with management targeting higher clinic revenue and greater operating efficiency. Planned service-fee increases are expected to add roughly JPY 15 million annually, with most of the contribution flowing to profit.
• Positive Sentiment: The company is broadening beyond aesthetics through non-aesthetic healthcare, international expansion, and new longevity offerings. It is targeting 1,000 clinics by 2035, while pursuing asset-light expansion in Southeast Asia and further growth with OrangeTwist in the U.S.
• Negative Sentiment: A weaker Japanese yen remains a headwind because most operations are yen-denominated, while competition in Japan has recently been intense. SG&A also increased, although management attributed much of the rise to one-time costs related to the secondary offering.

SBC Medical Group Price Performance

Shares of SBC traded down $0.14 during trading hours on Thursday, reaching $3.06. 225,017 shares of the company traded hands, compared to its average volume of 88,658. The stock has a market capitalization of $313.38 million, a PE ratio of 7.84 and a beta of 0.59. SBC Medical Group has a fifty-two week low of $2.78 and a fifty-two week high of $5.07. The company has a quick ratio of 3.78, a current ratio of 3.82 and a debt-to-equity ratio of 0.12. The stock has a fifty day simple moving average of $3.07 and a 200 day simple moving average of $3.57.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Wall Street Zen raised shares of SBC Medical Group to a "hold" rating in a report on Saturday, May 9th. Weiss Ratings downgraded shares of SBC Medical Group from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, May 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, SBC Medical Group currently has a consensus rating of "Hold" and a consensus price target of $8.50.

Hedge Funds Weigh In On SBC Medical Group

A number of hedge funds have recently made changes to their positions in the stock. Wells Fargo & Company MN grew its position in SBC Medical Group by 195.1% in the fourth quarter. Wells Fargo & Company MN now owns 12,626 shares of the company's stock valued at $54,000 after acquiring an additional 8,348 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of SBC Medical Group by 292.0% during the fourth quarter. Russell Investments Group Ltd. now owns 11,775 shares of the company's stock worth $51,000 after purchasing an additional 8,771 shares in the last quarter. Barclays PLC boosted its stake in shares of SBC Medical Group by 123.7% in the fourth quarter. Barclays PLC now owns 17,779 shares of the company's stock valued at $77,000 after purchasing an additional 9,831 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of SBC Medical Group in the fourth quarter valued at $49,000. Finally, Nuveen LLC acquired a new stake in SBC Medical Group during the 4th quarter valued at $53,000. Institutional investors and hedge funds own 60.82% of the company's stock.

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company's primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source